IPG Photonics Corporation (IPGP) Stock Price & How to Invest

IPG Photonics designs and builds fiber lasers, amplifiers and complete laser systems, and it is unusually vertically integrated: it makes its own semiconductor diodes, specialty fiber and optical components rather than buying them. That integration is what let it undercut older laser technologies on cost and reliability two decades ago. Revenue is reported in two segments. Industrial Solutions, about 85% of sales, supplies lasers that fabricators, carmakers, battery makers and general manufacturers use to cut, weld, clean, mark and 3D-print metal. Advanced Solutions covers medical, micromachining, scientific and defense work, including the CROSSBOW counter-drone laser system sold under the IPG Defense name. The company earns money mainly on equipment sales to machine builders and end users, plus a smaller stream of service, parts and accessories.

After several flat years, revenue is growing again. Second-quarter 2026 revenue (reported August 4) was about $278.6 million, up 11% from a year earlier, after about $265.5 million in the first quarter. Industrial Solutions grew 16% while Advanced Solutions fell 9%. GAAP gross margin improved to 40.4% from 37.3%, helped partly by $4.7 million of tariff refunds, and adjusted EPS nearly doubled to $0.58. GAAP net income was only about $5.2 million ($0.12 a share), because the quarter absorbed a $17.6 million impairment after IPG agreed to sell its operations in Belarus. Two other changes matter: a May 2026 agreement with TRUMPF ended all patent litigation between the two worldwide, and in July IPG made a binding offer to buy Lumibird Medical, a French ophthalmology laser maker, for EUR 300 million in cash.

The investment debate is about margins more than revenue. At its peak IPG ran gross margins above 50%, and lower-cost Chinese fiber-laser makers are a large reason it no longer does. Supporters point to an order book with book-to-bill above 1.0, emerging products that now make up 58% of sales, a medical acquisition expected to add to margins, and a balance sheet with no borrowings. Skeptics point to Q3 guidance that implies flat to lower revenue, a trailing GAAP P/E above 100, no share repurchases in the first half of 2026 despite a new $100 million authorization, and a stock that has fallen from a 52-week high of about $156 to around $71 in October 2026.

The biggest risk is the industrial capital-spending cycle. IPG sells equipment, so a slowdown in metal fabrication, autos or EV battery investment shows up in orders within a quarter or two, and the company's own Q3 guidance range (adjusted EPS of $0.30 to $0.60) is wide. Chinese fiber-laser makers such as Raycus and Maxphotonics have taken share in low and mid-power lasers, and pricing pressure in China, the world's largest laser market, is the main reason margins sit well below the 50%-plus of its peak years. GAAP profit is thin (TTM net income of roughly $28 million on about $1.07 billion of revenue), so impairments, litigation costs or tariff changes swing reported earnings sharply; management itself flagged trade and tariff uncertainty as a risk to the outlook. Advanced Solutions fell 9% in Q2, and CROSSBOW carries export-control exposure. Lumibird Medical still requires a French works-council consultation, a definitive agreement and regulatory approvals before it closes, and integrating a medical-device business is new territory for IPG. The Belarus sale also depends on regulatory approval.

7 analysts publish price targets on IPGP, averaging $124.14 against a $71.01 price as of October 2026, or +74.8%. The published targets run from $78.00 to $152.00, a moderate spread, and the ratings split 6 buy, 2 hold, 1 sell. Over the last six months there have been 2 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full IPGP forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on IPG Photonics Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Industrial demand recovery. Industrial Solutions revenue was about $237 million in Q2 2026, up 16% from a year earlier, and about $465 million for the first half, up 18%. The most optimistic published target, $152.00, assumes this works close to its best case.

The case against. The biggest risk is the industrial capital-spending cycle. The most pessimistic target, $78.00, is roughly what IPGP is worth if this bites instead.

Read the full bull and bear case on IPGP, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see IPG Photonics Corporation's investor relations page or your broker.

• Revenue (TTM): ~$1.07 billion
• Q2 2026 revenue: ~$278.6 million (up ~11% YoY)
• Q2 2026 EPS: $0.12 GAAP, ~$0.58 adjusted
• Gross margin (Q2 2026): ~40.4% GAAP (37.3% a year earlier)
• Cash and short-term investments: ~$871 million, no debt
• Market cap: ~$3.0 billion (about $71 a share, mid-October 2026)

Analysts expect about $1.12 billion of revenue and roughly $1.86 of adjusted EPS for 2026, rising to about $1.22 billion and $2.31 in 2027. At about $71 a share that is under 3 times sales and roughly 31 times forward earnings, while the trailing GAAP P/E is above 100 because reported profit is thin. Cash and short-term investments cover close to 30% of the market value. The valuation therefore rests on margins recovering toward historical levels, not on current GAAP earnings. The stock sits near its 52-week low of about $69 after peaking near $156.

Other names that sit close to IPGP: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get IPGP exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so IPGP sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where IPGP fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

IPGP is a debt-free, cash-rich fiber-laser leader whose revenue is growing again in 2026, but thin GAAP profit, Chinese price competition and the factory cycle will decide whether that recovery becomes durable earnings growth.

Whether IPGP is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is IPGP a buy or a sell?, and where the stock could go from here in the IPGP stock forecast.

For income investors, whether IPGP pays a dividend and how the payout looks is covered in does IPGP pay a dividend? And to weigh IPGP against a peer, read the full side-by-side comparisons: IPGP vs COHR and IPGP vs LASR.